Anti-tumour activity of T cells expressing chimeric receptors which incorporate both primary and costimulatory signalling sequences

被引：0
|
作者：
Lawson, ADG [1 ]
Finney, HM [1 ]
Moser, RN [1 ]
Bergin, M [1 ]
Suitters, A [1 ]
Antoniw, P [1 ]
Eddleston, A [1 ]
Weir, ANC [1 ]
机构：
[1] Celltech R&D Ltd, Slough SL1 4EN, Berks, England
来源：
CANCER GENE THERAPY | 2001年 / 8卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PD46
引用
收藏
页码：922 / 922
页数：1
相关论文
共 50 条
  • [31] In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models
    Argueta, Shannon
    Wang, Yuxiao
    Zhao, Hongyun
    Diwanji, Neha
    Gorgievski, Michael
    Cochran, Edward
    Grudzien-Nogalska, Ewa
    D'Alessandro, Josephine
    Mccreedy, Bruce
    Prod'homme, Thomas
    Hofmeister, Robert
    Ding, Jian
    Getts, Daniel
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [32] Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors.
    Barber, Amorette E.
    CANCER RESEARCH, 2021, 81 (13)
  • [33] T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
    Mihara, Keichiro
    Yoshida, Tetsumi
    Takei, Yoshifumi
    Sasaki, Naomi
    Takihara, Yoshihiro
    Kuroda, Junya
    Ichinohe, Tatsuo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [34] T Cells Bearing Anti-CD19-and/or Anti-CD38-Chimeric Antigen Receptors Effectively Abrogate Primary Double-Hit Lymphoma Cells
    Mihara, Keichiro
    Yoshida, Tetsumi
    Takei, Yoshifumi
    Sasaki, Naomi
    Takihara, Yoshihiro
    Ichinohe, Tatsuo
    BLOOD, 2016, 128 (22)
  • [35] T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
    Keichiro Mihara
    Tetsumi Yoshida
    Yoshifumi Takei
    Naomi Sasaki
    Yoshihiro Takihara
    Junya Kuroda
    Tatsuo Ichinohe
    Journal of Hematology & Oncology, 10
  • [36] The signalling signature downstream of the notch receptor in CD4+CD25highregulatory T cells in RA defines anergic cells: insight into resistance to anti-tumour necrosis factor therapies
    MH Buch
    K Snow
    S Field
    P Emery
    J Isaacs
    F Ponchel
    Arthritis Research & Therapy, 7
  • [37] Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D
    Zhongjuan Wang
    Linghua Guo
    Yuan Song
    Yinsheng Zhang
    Dandan Lin
    Bo Hu
    Yu Mei
    Dedy Sandikin
    Haiyan Liu
    Cancer Immunology, Immunotherapy, 2017, 66 : 537 - 548
  • [38] Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D
    Wang, Zhongjuan
    Guo, Linghua
    Song, Yuan
    Zhang, Yinsheng
    Lin, Dandan
    Hu, Bo
    Mei, Yu
    Sandikin, Dedy
    Liu, Haiyan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (04) : 537 - 548
  • [39] The signalling signature downstream of the notch receptor in CD4+CD25high regulatory T cells in RA defines anergic cells:: insight into resistance to anti-tumour necrosis factor therapies
    Buch, M. H.
    Snow, K.
    Field, S.
    Emery, P.
    Isaacs, J.
    Ponchel, F.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S11 - S11
  • [40] Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells
    Supimon, Kamonlapat
    Sangsuwannukul, Thanich
    Sujjitjoon, Jatuporn
    Chieochansin, Thaweesak
    Junking, Mutita
    Yenchitsomanus, Pa-thai
    CYTOTHERAPY, 2023, 25 (02) : 148 - 161
12345